India’s drug regulator is implementing inspection guidelines. The Wall Street Journal reports that the regulator has established an inspection framework that may do away with the haphazard nature of recent inspections.
The FDA has banned imports from four Ranbaxy laboratories after uncovering massive transgressions, and its parent company Sun Pharmaceuticals has also had its share of FDA hand-slaps.
The WSJ notes the FDA has upped its inspections of late, with 111 last year, up from 98 in 2011 and 59 in 2009.
